Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FK228 Continuation Study in Metastatic Renal Cell Carcinoma and Prostate Cancer
NCT00106301Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of romidepsin in renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), sponsored by Celgene Corporation. Started Apr 2004; status: completed.
02
Drugs
romidepsin
03
Conditions
renal cell carcinoma (RCC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00106301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00106301.